Skip to content

Effect of alpha 2 receptor agonist on reducing cerebral hyperperfusion syndrome after intravascular treatment in patients with chronic stroke

Effect of alpha 2 receptor agonist on reducing cerebral hyperperfusion syndrome after intravascular treatment in patients with chronic stroke

Status
Active, not recruiting
Phases
Phase 4
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR1900024416
Enrollment
Unknown
Registered
2019-07-10
Start date
2019-07-20
Completion date
Unknown
Last updated
2023-05-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Cerebrovascular disease

Interventions

Dexmedetomidine group:Dexmedetomidine was used for 72 hours postoperatively
Normal saline group:Normal saline was applied for 72 hours after operation

Sponsors

He'nan Provincial People's Hospital
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 75 Years

Inclusion criteria

Inclusion criteria: 1. Aged >= 18 years; 2. Arterial angiography obstruction greater than 2mm intracranial >= 70%; 3. Patients with cerebral vascular stenosis are expected to receive endovascular treatment; 4. MRS 2 or less; 5. Dexmedetomidine was approved by the interventional neurologist and anesthesiologist.

Exclusion criteria

Exclusion criteria: Any of the following will be excluded from this study: 1. Imaging examination could not determine whether there was infarction and vascular obstruction; 2. Intracranial hemorrhage; 3. Known allergy to analgesics or sedatives (including dexmedetomidine); 4. Coma on admission (Glasgow coma scores less than 8 points); 5. NIHSS is less than 10 points; 6. Agitation or epilepsy at admission; 7. Loss of airway protective reflex and/or vomiting; 8. Endotracheal intubation was performed before treatment on admission; 9. Known allergy to anesthetics or analgesics.

Design outcomes

Primary

MeasureTime frame
Cerebral hyperperfusion syndrome, CHS;TCD;MRI;NIHSS;Living conditions;

Countries

China

Contacts

Public ContactChang Enqiang

He'nan Provincial People's Hospital

changenqiang@henu.edu.cn+86 15890125781

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 6, 2026